An analytical review on schizophrenia pharmaceutical treatment along with intelligent retrieval

Saumya Das
Associate Professor at Noida Institute of Engineering & Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, Uttar Pradesh-201306.
Corresponding author email: awasthi.saumya22@gmail.com
ORCID: 0000-0002-8531-9963

Madhvi Singh
M.Pharm (Pharmacology), Noida Institute of Engineering & Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, Uttar Pradesh-201306.
Email: madhvithakur12599@gmail.com
ORCID: 0000-0003-1396-7731

Komal Singh
M.Pharm (Pharmacology), Noida Institute of Engineering & Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, Uttar Pradesh-201306.
Email: komalsinghgahlot440@gmail.com
ORCID: 0000-0001-7807-0357

Ayush Atri
M.Pharm (Pharmacology), Noida Institute of Engineering & Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, Uttar Pradesh-201306.
Email: ayushatri06@gmail.com
ORCID: 0000-0003-4499-6869

Abstract---Suicidal thoughts, higher use of resources like hospitalisation and related costs, and clinical deterioration may occur if schizophrenia patients fail to adhere to their drug regimens, according to a new study. We are analysing data from clinical trials of therapy that aim to boost the proportion of patients with schizophrenia who adhere to their medication. Nonadherence to therapy is a problem that affects both patients and healthcare providers. Behavioral treatment, long acting injectables (LAI), and antipsychotics based on methamphetamine LAI technology are a few examples. Only a small number of smartphone applications, such as medicine monitors and voice assistants, have been integrated with AI. The inclusion of clinically relevant samples in randomised, controlled, and blinded studies is necessary to measure not just adherence but

8527

also clinically important and long-lasting treatment outcomes for schizophrenia patients.

Keywords---Schizophrenia, Anti-psychotics, Drug related factors, Intelligent retrieval.

Introduction

A comprehensive treatment plan that includes antipsychotic medication is necessary since schizophrenia is a long-term and debilitating illness. (Baldessarini, 2013; Yan & Greene *et al.*, 2018; Clifford & Crabb *et al.*, 2020). Recent research indicated that quitting psychopharmacological treatment increased clinical decline rates by five times in patients with chronic psychosis (El Khoury & Pilon *et al.*, 2020) a dozen times more likely to take their own life. (Forsman & Taipale *et al.*, 2019). Patients who do not adhere to prescribed antipsychotic drug therapy face an increased risk of hospitalisation, a worsening of their general health and well-being, and an increase in healthcare costs (Nielsen & Jensen *et al.*, 2015; Phan, 2016). In contrast, the long-term use of antipsychotics may lead to significant decreases in mortality and improved clinical results (Taipale & Tanskanen *et al.*, 2020). Errors or noncompliance with antipsychotic drug regimens are rather common. Patients using oral formulations were found to have a prevalence that ranged from 20% to 89% (Barkhof & Meijer, 2012), 55 percent of the population (Phan, 2016). The source of the issue is a combination of patient characteristics, drug-related variables, and the kind of professional services supplied (Clifford & Crabb *et al.*, 2020; Fleischhacker, 2013; Ostuzzi & Mazzi *et al.*, 2018; Higashi K, Medic G *et al.*, 2013).

Side effects, tolerance, and other medication-related difficulties might affect how well patients stick to their treatment plans. Treatment non-adherence in schizophrenia patients is strongly linked to other illness-related difficulties, such as poor health literacy and inconsistency in access to prescribed medicines, which are also linked to disorientation (Clifford & Crabb *et al.*, 2020). Poor adherence to prescribed medication is also associated with severely symptomatic illness and co-occurring substance use disorders, resulting in a cycle of diminishing treatment effectiveness and clinical worsening. (Baldessarini, 2013; Czobor & Van Dorn *et al.*, 2015).

After discontinuing antipsychotic medication, 40% of schizophrenia patients got an understanding of the need of continuing therapy after experiencing deterioration in their condition upon discontinuation (Tranulis & Goff *et al.*, 2011). Concerns about stigma and ignorance about one's sickness may hamper one's willingness to receive treatment (Tranulis & Goff *et al.*, 2011), as well as the unpleasant antipsychotic pharmaceutical side effects and the remission of these side effects following withdrawal of the medication (Baldessarini, 2013; Velligan & Weiden *et al.*, 2009).

If clinicians in responsive and supportive clinical care systems have a good therapeutic relationship with their patients and their families are engaged, they may help them adhere to their treatment programmes (Sendt & Tracy *et al.*, 2015). There are also a variety of technological approaches that may help patients stick to their medication regimen, including medication trackers, missed-dose alerts, activity check

lists and frequent phone calls from their doctor or pharmacist, all of which will be explored further on in this article (Barkhof & Meijer, 2012; Kreyenbuhl & Record *et al.*, 2016). Early research assistance has been supported by a number of programmes, although these efforts have not been well explored (Clifford & Crabb *et al.*, 2020; Fleischhacker, 2013; Ostuzzi & Mazzi *et al.*, 2018; Higashi K, Medic G *et al.*, 2013; Czobor & Van Dorn *et al.*, 2015).

It is well accepted that early diagnosis and monitoring of drug non-adherence in schizophrenia patients is essential for long-term antipsychotic treatment. Non-adherence assessment in clinical practise, on the other hand, continues to be a problem that requires more research (Nielsen & Jensen *et al.*, 2015; Kane & Kishimoto, 2013). For the sake of best therapeutic results, this review analyses new research on the variables that influence drug adherence in schizophrenia patients and assesses ways for boosting the adherence to prescription antipsychotic drugs.

1. Measuring Drug-Treatment Adherence In Schizophrenia

The outcomes of clinical study examining adherence may be influenced by the criteria and procedures employed to measure treatment nonadherence (Phan, 2016). A patient's reluctance to take their medicine or a change in their medication dose may both result in treatment nonadherence (either purposeful or accidental). In clinical practise and experimental treatment research, it is critical to accurately assess nonadherence, particularly in disorders like schizophrenia that are notoriously difficult to treat (Nielsen & Jensen *et al.*, 2015; Kane & Kishimoto, 2013). Many objective and subjective techniques have been offered and some have been tested (Bright, 2017). Direct observation of pill consumption, patient treatment diaries, periodic pill counting, and electronic monitoring tools are some of the methods that may be employed (*therapeutic drug monitoring* (TDM)). Patient questionnaires and symptom rating scales may be used to acquire information from patients regarding their medication use, and the latter can be used to assess the effectiveness of the treatment (Bright, 2017).

There have been contradictory findings in the use of objective measures to evaluate treatment adherence because correlations between multiple objective measures are not necessarily concordant and may be impacted by several clinical and technical variables (Velligan & Weiden *et al.*, 2009; Velligan & Wang *et al.*, 2007; Brain & Sameby *et al.*, 2014). Adherence seems to be overestimated by subjective assessments (Velligan & Wang *et al.*, 2007). Some researchers have expressed doubts about the validity or reliability of subjective measures (such as patient and clinician-rating scales) that are often employed in schizophrenia treatment adherence assessments. A number of subjective approaches have shown early indications of considerable validity, reliability, and sensitivity in these patients, however. Among them are the *Episode-Specific Approach* (ESA), *the Brief Adherence Rating Scale* (BARS), and *the Medication Adherence Rating Scale* (MARS) (Bright, 2017; Velligan & Wang *et al.*, 2007).

Simple pill-counting is an objective metric (Brain & Sameby *et al.*, 2014) Moreover, medication access is monitored electronically with the use of devices and reporting procedures. A *Medication Event Monitoring System*, a medicine bottle-cap with a microprocessor that records the incidence and time of each bottle opening, but not necessarily pill-taking, is one example of such techniques

(Brain & Sameby *et al.*, 2014; Lee & Lee *et al.*, 2019). Discarding medication and failing to record actual intake are some of the limitations of these systems (Kane & Kishimoto, 2013). Another problem is that patients, especially those with long-term mental health issues like schizophrenia, may not follow the prescribed treatment plan exactly as prescribed. In addition, some electronic monitoring technologies are pricey and may not be appropriate for many community settings (Velligan & Wang *et al.*, 2007; Lee & Lee *et al.*, 2019). These procedures are less costly and time consuming, but they may overstate patient adherence (Lee & Lee *et al.*, 2019). For the purpose of proving that a patient has ingested medication, a blood test to measure circulating levels of the drug is a helpful tool. Intrusive and impacted by individual variability in pharmacokinetics and metabolism, as well as blood sampling time (Hiemke & Bergemann *et al.*, 2018). A lack of knowledge with and training in treatment adherence evaluation tools has kept rating scales and other measurement-based techniques from being widely used in normal clinical psychiatric care (Kane & Correll, 2020).

Aiming to identify and assess treatment adherence evaluation methodologies, as well as treatments aiming at enhancing treatment adherence, we conducted this review. By kind of intervention evaluated, data are arranged according to the influence on treatment adherence among schizophrenia patient-subjects who meet standard criteria.

2. Drug-Related Risk Factors

Adherence problems with prescribed oral antipsychotic medication therapy may be exacerbated by inadequate perceived benefit, especially when contrasted to unpleasant side effects of specific drugs in individual patients, as well as high dosages or inappropriate complexity of drug combinations. Long-acting injectable formulations of effective antipsychotic drugs have been explored extensively to decrease some of these nonadherence causes.

3. Long-Acting Injected Antipsychotics

Antipsychotics with long-acting injectable (LAI) action are becoming more widely available, and this may help patients better adhere to their medication regimens. Fluphenazine and haloperidol's decanoate esters were launched onto the market decades ago (Baldessarini, 2013), Several more SGAs have been added to the collection. Although these treatments are currently underutilised in many cultures, the costs associated with providing them, as well as the extra facilities and employees they need, may be high. LAI antipsychotics are used by about 15–28 percent of schizophrenia patients in the United States; only around 40 percent of European clinicians would use a LAI antipsychotic as the primary treatment in the United States, according to a study (Fiorillo & Barlati et al., 2020). Patients' and society's attitudes about and opinions of LAI pharmaceuticals, as well as concerns about possible severe side effects and the difficulty to rapidly stop treatment owing to the nature of LAI medicines, may all hamper their acceptance. SGA antipsychotics, in particular, have been shown to be hazardous to patients, despite this (Ostuzzi & Mazzi et al., 2018; Mohr & Knytl et al., 2017), Compared to orally delivered drugs, intravenous therapy may enhance treatment adherence and clinical outcomes in people with schizophrenia (Table 1). Retrospective or

"mirror-image" (within-subject comparisons done after and before the administration of LAI medicines) analysis and other assessments of clinical changes are used instead of prospective investigations, such as exploratory, randomised clinical trials. A number of factors were considered in these studies, such as the discontinuation rate, the number of expired prescription refills, the time elapsed between the time of the last refill and the actual discontinuation, and the percentage of days covered by a prescription, all of which were derived from databases (an estimate of the proportion of time with drug available, though not necessarily taken) (Yan & Greene et al., 2018; Gutiérrez-Casares & Cañas et al., 2010; Yoshimatsu & Elser et al., 2019).

It's hardly unexpected that patients on LAI had a greater percentage of adherence than those taking other oral antipsychotics (Table 1). Adherence to LAI antipsychotics varied from 68% to 81%, but oral antipsychotics were only adhered to by 24% to 52% of patients (Table 1). Predicted medication availability for LAI using first and second-generation antipsychotics was shown to have much lower discontinuation rates than oral formulations (Table 1). Prescription compliance with oral antipsychotics was tracked using MEMS, which counts the number of medication containers opened but does not record the number of pills consumed (Gutiérrez-Casares & Cañas et al., 2010). When coupled with a LAI antipsychotic, the adherence of patients with early psychosis to oral formulations was observed to increase (75 percent vs. 32 percent) (Titus-Lay & Ansara et al., 2018). Owing to the increasing frequency of visits to mental health facilities due to the administration of LAI antipsychotics, or the improved mental health afforded by injectable medicine, this relationship may be attributed.

It is important to compare the effectiveness of LAI vs. oral antipsychotic drug therapy in order to improve treatment adherence. Compared to other medicines included in this analysis, clinical efficacy has been investigated in retrospective studies and in randomised controlled trials substantially more often. Clinical effectiveness differences between LAI and orally administered antipsychotics in mirror-image investigations were much greater than in prospective, randomised trials when the two were compared (Kishimoto & Hagi et al., 2018; Kishimoto & Nitta et al., 2013). 60% of randomised, comparative trials found that clinical exacerbations were prevented when LAI preparations were not significantly superior in preventing the overall incidence of illness-exacerbations (Mohr & Knytl et al., 2017; Gutiérrez-Casares & Cañas et al., 2010). Though LAI has been shown in certain randomised studies to offer stronger therapeutic benefits than oral antipsychotics (Alphs & Benson et al., 2015; Subotnik & Casaus et al., 2015).

Research comparing behaviour before and after an intervention (such as LAI antipsychotic treatment) has demonstrated greater outcomes than prospective, randomised trials, in contrast to retrospective or mirror image research. As a precaution against selection bias, researchers may exclude patients who have previously failed to adhere to treatment, such as those with substance abuse or co-occurring mental illness, from some RCTs. However well publicisedthe intervention may be, subjects' and researchers' expectations of a new intervention may distort mirror-image comparisons in favour of favourable outcomes.

Table 1. Adherence to treatment with long-acting injectable vs. oral antipsychotics

Report	Design	Drugs (n)	Subjects (n)	Adherence Measure	Outcome
Kishimoto *et al.* 2014 (34)	Metan	FGA-LAIs SGA-LAIs OAs	955 LAIs 1063 OAs	All-cause dc	dc: LAIs = OAs
Alphs *et al.* 2015 (35)	RCT	LAI-PAL OAs	226 LAI – PAL 218 OAs	MPR; dc rate (& latency)	MPR: LAI>OAs (40%/24%); dc rate: LAI<OAs
Marcus *et al.* 2015 (36)	Retro	FGA-LAIs SGA-LAIs OAs	157 FGA LAIs 183 SGA LAIs 3428 OAs	PDC; Rx gap ≥60d	PDC: LAIs>OAs; PDC: SGAs>FGAs
Subotnik *et al.* 2015 (37)	RCT	RSP-LAI RSP-OA	27 RSP-LAI 30 RSP-OA	All-cause dc	RSP-LAI = RSP-OA
Pilon *et al.* 2017 (38)	Retro	SGA-LAIs OAs	3307 SGA-LAIs 21,355-OAs	PDC	PDC: LAIs>OAs
Verdoux *et al.* 2017 (39)	Retro	FGA-LAIs SGA-LAIs OAs	104 FGA LAIs 184 SGA LAIs OAs	All-cause dc	dc rate: LAIs<OAs
Vincent *et al.* 2017 (40)	Metan	LAI-PAL OAs	114 total	MPR	MPR: LAI>OAs (81%/43%)
Greene *et al.* 2018 (41)	Retro	FGA-LAIs SGA-LAIs OAs	927 FGA-LAIs 1934 SGA-LAIs 2777 OAs	PDC or ≥60-day Rx-gap	Adherence LAIs>OAs by 5%; Discontinue: LAIs<OAs by 20%
Kishimoto *et al.* 2018 (42)	Metan	FGA-LAIs SGA-LAIs OAs	562 FGA LAIs 3773 SGA LAIs 32,258 OAs	All-cause dc	dc: LAIs<OAs
Shah *et al.* 2018 (43)	Retro	LAIs OAs	2302 LAIs 2302 OAs	PDC dc; dc rate	PDC: LAIs = OAs; dc rate: LAIs<OAs
Suzuki *et al.* 2018 (44)	Obs	SGA-LAIs PP-OA	406 SGA-LAIs 432 PP-OA	All-cause dc & Time to dc	dc rate: SGA-LAIs = PP-OA Dc latency: SGA-LAIs>PP-OA
Titus-Lay *et al.* 2018 (45)	Retro	FGA-LAIs SGA-LAIs OAs	35 OAs 4 SGA LAIs	PDC; Lack of Rx-gap	Adherence: LAIs>OAs (76%/32%)
Yan *et al.* 2018 (2)	Retro	APZ-LAI OAs	408 APZ-LAI 3361 OAs	PDC; d/c rate & latency	PDC: LAI>OAs dc rate: LAI<OAs
Song *et al.* 2019 (46)	Retro	SGA-LAIs OAs	6344 LAIs 7029 OAs	≥60-day Rx-gap	Persistence: SGA-LAIs>OAs
Yoshimatsu *et al.*2019 (47)	Obs	LAIs OAs	77	Rx duration	Adherence: LAIs>OAs

D, days; dc, discontinuance; AAs, antipsychotic drugs first generation antipsychotic FGA; injectable antipsychotic LAI; long-term antipsychotic treatment Medication Event Monitoring System (MEMS) - Meta-analysis, or simply

"meta" oral antipsychotic OA; observational study Obs; MPR: Medication Possession Ratio Pharmacist-Filled Prescription Days (PDC) Prospective RCTs using paliperidone are called RCTs with prospective randomization. SGA is a second-generation antipsychotic; RSP is for risperidone; Rx stands for prescription. It is worth noting that 16/21 research (76.2 percent) showed evidence of greater treatment adherence with the use of LAI antipsychotics: 12/14 (85.7 percent) of observational or retrospective studies, and 4/7 (57.1 percent) of RCT or meta-analyses ($x2 = 2.10$, $p = 0.15$).

4. Countering Other Drug-Related Factors

Lack of apparent therapeutic benefit, side effects, previous poor experiences with comparable therapies, and the complexity of the medication regimen (many medicines and doses/day) all tend to have a detrimental impact on treatment adherence with antipsychotic drugs (Phan, 2016; Sendt *et al.*, 2015; Kane *et al.*, 2013). For example, we were unable to locate trials evaluating particular strategies to improve compliance with such prevalent clinical criteria. In spite of this, good clinical practise calls for a low dose administered just a few times each day (1). In addition, patients should be warned of possible side effects, and they should be monitored and intervened on a regular basis in order to reduce the negative consequences (Phan, 2016; Baldessarini, 2013). Despite the fact that antipsychotic combos may be effective in certain cases (49), In contrast to optimal monotherapy, such polytherapy has seldom been fully tested for safety and effectiveness. Discomfort and side effects are increased, as is the expense, and treatment compliance is harmed when many medications are used (Phan, 2016; Baldessarini, 2013). Clozapine is the only antipsychotic medicine that has not been shown to lower the risk of mental hospitalisation in comparison to other antipsychotics, according to an extensive meta-analysis evaluating the effects of single vs. multiple antipsychotic regimens (Tiihonen *et al.*, 2019). That research, however, did not examine treatment adherence in relation to treatment complexity explicitly.

5. Lack Of Insight

Schizophrenia treatment adherence is affected by a patient's ongoing psychotic symptoms, insight, attitude toward drugs, and capacity to reflect on prior experiences. Nonadherence was shown to be connected with patient perceptions of elements such as the denial of mental disease in a recent qualitative investigation, particularly early in the course of psychotic illness (Clifford *et al.*, 2020). The researchers in the same study also discovered that improved treatment adherence was linked to the capacity to remember previous unpleasant symptoms that were present before therapy and their improvement with treatment (Clifford *et al.*, 2020). In a meta-analysis of 1154 individuals from two major clinical studies, it was shown that co-occurring drug addiction was likewise linked to poor treatment adherence among patients with schizophrenia, leading to the same results (Czobor *et al.*, 2015). Studies have shown that being able to recognise that you have a medical condition is linked to better adherence (Velligan *et al.*, 2009; Tessier *et al.*, 2017). Symptom severity, neurocognitive performance, perceived stigma, and other characteristics linked with psychotic disease are likely to influence insight (Baldessarini, 2013; Nielsen *et al.*, 2015)

Increasing self-awareness, self-reflection, and a positive outlook toward therapy are all goals in studies of various psychological therapies. A wide range of findings have been obtained (Table 2) (Anderson *et al.*, 2017; Staring *et al.*, 2010; Barkhof *et al.*, 2013; Schulz *et al.*, 2013; Chien *et al.*, 2015; von Bormann *et al.*, 2015; Abdel *et al.*, 2016; Chien *et al.*, 2016; Yanagida *et al.*, 2017; Cetin *et al.*, 2018; Ertem & Duman, 2019; Chien *et al.*, 2019; Tatu & Demir, 2020; Yildiz & Aylaz, 2021) see the next section for further information.

6. Psychosocial Interventions

Several psychosocial therapies have been studied in recent decades to see whether they affect treatment adherence in people with schizophrenia. Patients in hospitals and those who are ambulatory may benefit from motivational interviewing, adherence treatment, and other types of psychoeducation (Table 2) (Anderson *et al.*, 2017; Staring *et al.*, 2010; Barkhof *et al.*, 2013; Schulz *et al.*, 2013; Chien *et al.*, 2015; von Bormann *et al.*, 2015; Abdel *et al.*, 2016; Chien *et al.*, 2016; Yanagida *et al.*, 2017; Cetin *et al.*, 2018; Ertem & Duman, 2019; Chien *et al.*, 2019; Tatu & Demir, 2020; Yildiz & Aylaz, 2021). Patient-centered, directed motivational interviewing aims to explore and resolve patient ambivalence regarding diagnosis and treatment in order to increase their drive to improve (Song *et al.*, 2019). It was initially intended for patients who were struggling with substance misuse. Small, controlled trials with mixed results have been conducted on persons with psychotic diseases that have been customised to their needs (Table 2) (Barkof *et al.*, 2013; Schulz *et al.*, 2013; Chien *et al.*, 2015; von Bormann *et al.*, 2015; Abdel *et al.*, 2016; Chien *et al.*, 2016; Yanagida *et al.*, 2017; Cetin *et al.*, 2018; Ertem & Duman, 2019). Patients and clinicians may work together in adherence therapy to come up with treatment options that are more meaningful and enjoyable for them. It is based on the ideas of motivational interviewing and cognitive behavioral therapy (CBT) (Chien *et al.*, 2019). Antipsychotic therapy has a variety of strategies, including cooperative problem-solving, sharing knowledge, and examining ambivalence (Chien *et al.*, 2019). Some controlled studies of adherence therapy have shown variable results, however extended treatment over 12–18 months resulted in better treatment adherence outcomes (Table 2) (Anderson *et al.*,2017; Staring *et al.*, 2010; Schulz *et al.*, 2013; ; von Bormann *et al.*, 2015; Chien *et al.*, 2016; Tatu & Demir, 2020). Assessment of outcomes was improved by using Adherence Rating (ARS) and Medication Adherence Rating (MARS) measures rather than a larger 30-item Drug Attitude Inventory (DAI-30) (Table 2).

Patients and their families may be educated on the causes, symptoms, treatment, and prognosis of certain mental diseases via organized educational programs. It seeks to help patients acknowledge and accept that they have a disease, encourage motivation to better the condition, and boost self-esteem through enhancing patients' and their families' understanding and treatment of the illness (Tatu & Demir, 2020). At least four studies of varied types have tested these therapies in the recent past (Abdel *et al.*, 2016; Yanagida *et al.*, 2017; Cetin *et al.*, 2018; Ertem & Duman, 2019; Chien *et al.*, 2019; Tatu & Demir, 2020; Yildiz & Aylaz, 2021; Gray *et al.*, 2016; Montes *et al.*, 2010). Following a group or individual psychoeducational program was shown to enhance medication adherence in all these investigations; however, the longevity of these effects is unknown since follow-up evaluations lasted only 1–12 weeks (Table 2).

Table 2. Psychosocial interventions on treatment adherence among schizophrenia patients

Report	Method	Design	Setting	Subjects (n)	Sessions & Months	Final Months	Adherence Measure	Outcome
Anderson *et al.* 2010 (51)	AT	RCT	OPD	12 AT 14 TAU	8 2.0	2.0	PETiT	AT = TAU
Staring *et al.* 2010 (52)	AT	RCT	OPD	53 AT 52 TAU	—— 6.0	12	Interview	AT>TAU
Barkhof *et al.* 2013 (53)	MI	RCT	OPD (nonadherent)	55 MI 59 TAU	8 6.5	12	MAQ DAI	MI = TAU
Schulz *et al.* 2013 (54)	AT	RCT	OPD (newly dc)	80 AT 57 TAU	8 ——	3.0	CDR MARS DAI-30	AT = TAU
Chien *et al.* 2015 (55)	AT	RCT	OPD	57 AT 57 TAU	8 4.0	6.0	ARS	AT>TAU
Von Bormann *et al.* 2015 (56)	AT	RCT	OPD (newly dc)	38 AT 32 TAU	8 ——	6.5	DAI-30	AT = TAU
Abdel Aziz *et al.* 2016 (57)	IP	QE	Inpatients to dc	82 IP 39 TAU	5 ——	1.5	Pill-count Rx diary	IP>TAU
Chien *et al.* 2016 (58)	AT	RCT	OPD	67 AT 67 TAU	6 3.0	18.0	ARS	AT>TAU
Yanagida *et al.* 2017 (59)	GP	Open	Hospitalized	70 GP	6 ——	0.25	DAI-10	DAI-10 score improved
Cetin & Aylaz 2018 (60)	MGP	RCT	OPD	55 MGP 80 TAU	8 1.0	1.0	MARS	MGP>TAU
Ertem *et al.* 2018 (61)	MI	RCT	OPD	20 MI 20 TAU	6 ——	6.0	MAS	MI>TAU

Chien *et al.* 2019 (62)	AT+MI	RCT	OPD (nonadherent)	67 AT+MI 67 TAU	6 3.0	12	ARS	AT+MI>TAU
Tatu *et al.* 2020 (63)	GP	QE	OPD	24 GP 21 TAU	8 ——	3.0	MARS	GP>TAU
Yildiz *et al.* 2020 (64)	ACT+MI	QE	OPD	36 MI+ACT 51 TAU	8 ——	2.0	Interview	Motivation: ACT+MT>TAU

7. Behavioral Interventions

To help individuals with schizophrenia take their medication on a daily basis when previous psychosocial therapies had had uneven or inconclusive outcomes, numerous individually designed behavioural techniques were devised (Clifford *et al.*, 2020; Kreyenbuhl *et al.*, 2016; Gray *et al.*, 2016). There are a number of treatments that may be used in conjunction with these tactics, including reminders from pharmacies, financial or other reinforcements, computerised monitoring and apps for mobile phones (Table 3) (Kreyenbuhl *et al.*, 2016; Montes *et al.*, 2010; Granholm *et al.*, 2012; Montes *et al.*, 2012; Velligan *et al.*, 2013; Beebe *et al.*, 2014; Beebe *et al.*, 2016; Dahan *et al.*, 2016; Beebe *et al.*, 2017; Kidd *et al.*, 2018; Xu *et al.*, 2019; Uslu & Buldukoglu, 2020). A professional therapist visits the patient's house every week for 30 to 45 minutes for PharmCAT, whereas Cognitive Adaptation Training (CAT) employs visual aids such as signs, labels, and checklists to help patients remember to take their medication. Efficacy of these techniques has been investigated in at least two controlled trials in the recent past (Beebe *et al.*, 2014), with promising results that may last for some time (Table 3).

When a pharmacy for schizophrenia patients used an electronic medication monitor that alerted treatment personnel if a patient was taking the incorrect drug or at the wrong time, medication adherence increased significantly above randomised treatment as usual (TAU) (Beebe *et al.*, 2014). Adherence was raised by as much as 92 percent with the use of both in-person and electronic interventions (Beebe *et al.*, 2014). At the end of the four-month follow-up period, distributing a handbook to the patient's family members to urge their general support of the patient's treatment had no effect on adherence (Uslu & Buldukoglu, 2020).

Pharmacists may help patients manage their medication by providing them with individually packaged medicines and sending them reminders to renew their prescriptions. They can also notify their prescribing doctors when a patient hasn't filled a prescription on time. Because it included individuals with diagnoses other than schizophrenia, the approach was tested in a randomised controlled study that isn't included in Table 3 (Valenstein *et al.*, 2011). At a 12-month follow-up, it

found indications of much higher treatment adherence than in routine clinical care.

Even with LAI antipsychotics, there is a chance of non-compliance due to the frequency of clinic visits necessary for injections. Two controlled studies have assessed the use of financial incentives to promote treatment adherence using LAI antipsychotics rather than orally given medicines. In both cases, the increased incentives resulted in much more adherence than without them (Priebe *et al.*, 2016; Priebe *et al.*,2013).

Several randomised controlled studies assessed the treatment adherence of patients receiving or not receiving telephone-based therapy. Unstructured weekly phone calls from nurses to 847 outpatients with schizophrenia were shown to improve treatment compliance and attitudes regarding medication. There was a 97% increase in investigator-rated treatment compliance over TAU after the intervention across at least four months (Kreyenbuhl *et al.*, 2016). Using the MARS questionnaire, 140 outpatients with schizophrenia failed to show a meaningful improvement after two months of treatment (Beebe *et al.*, 2016).

Telephone Strategy-Problem Solving (TIPS) is another manual-guided telephone-based intervention that includes nurses trained to manage a range of community living challenges that are considered to impair treatment adherence (Beebe *et al.*, 2014; Beebe *et al.*, 2017). It was put through its paces in three randomised studies (Table 3). Using pill counts over a three-month period, a small study including 28 patients with psychotic disorders revealed no significant differences in adherence (78 percent–85 percent) among those who received TIPS phone calls on a weekly vs. daily basis (Beebe *et al.*, 2014). Over the course of six months, 105 outpatients with schizophrenia participated in a study that found no improvement in pill count adherence, but substantial increases in the percentage of participants with blood medication concentrations regarded to be within a therapeutic range (Beebe *et al.*, 2017). An additional controlled experiment with 46 outpatients with schizophrenia found that TIPS led to improved MARS compliance scores after two months of therapy (Beebe *et al.*, 2014).

The efficacy of a treatment named LEAN was investigated in a big clinical trial. Medicine reminders, health education and monitoring may be provided through nonprofessional help or mobile messaging. Outpatients with schizophrenia were studied in rural China by researchers (Xu *et al.*, 2019). Adherence to LEAN was much higher than TAU after six months of therapy.

For schizophrenia patients, MATS (Mobile Asses sment and Treatment for Schizophrenia) was intended as an additional mobile phone-based cognitive-behavioral intervention to improve treatment adherence, socialising, and notably to reduce auditory hallucinations. 42 out of the 55 participants who began it and completed it in a scientific experiment were randomly selected. Self-report text messages show that patients who are able to live independently and complete the 12-week treatment programme have significantly improved adherence (Granholm *et al.*, 2012).

Using 60 hospitalised schizophrenia patients, a randomised, controlled study examined the effectiveness of a personalised intervention aimed at increasing adherence to antipsychotic medication therapy. An average of six sessions of psychoeducation, motivational interviewing, and cognitive behavioural therapy (CBT) were used in the intervention to help patients achieve and maintain treatment adherence. TAU had considerably worse adherence and attitudes toward medicine at the conclusion of therapy, but there was no evaluation of long-term retention of the impact (Dahan *et al.*, 2016).

Research designs, intensity and length of treatments, and adherence measurements limit meaningful comparisons of the reported behavioural therapies. Patients' desire and capacity to comply with such therapies may also change over time based on their impressions of how they affect their privacy and independence. An individual strategy to balancing patient choices and the continued efforts of their doctors to prevent drop-out risk or treatment rejection is necessary.

Table 3. Quantitative comparisons of the several reported behavioral interventions

Report	Intervention Type	Study design	Setting	Subjects (n) & Interventions	Adherence Measure	intervention (mos)	Follow-up (mos)	Outcome
Montes *et al.*, 2010 (66)	Weekly TI vs TAU	RCT	OPD	409 TI 438 TAU	Interview	3.0	4.0	TI>TAU (96.7%, 91.2%)
Granholm *et al.*, 2012 (67)	MATS +payments	Open	OPD	42 MATS	Self-report	3.0	3.0	Adherence not improved
Montes *et al.*, 2012 (68)	Daily TM vs TAU	RCT	OPD	100 TM 154 TAU	MAQ	3.0	6.0	TM>TAU
Velligan *et al.*, 2013 (69)	PharmCAT vs eMM vs TAU	RCT	OPD	47 PharmCAT 48 eMM 47 TAU	Pill-count eMM	9.0	9.0	Both>TAU (90.5%,72%)
Beebe *et al.* 2014 (70)	Weekly TIPS ± Daily text	RCT	OPD	10 TIPS 10 texts 8 both	Pill-count	3.0	3.0	All similar
Beebe *et al.* 2016 (71)	TI	RCT	OPD	140 Total	MARS	3.0	3.0	TI = TAU
Dahan *et al.*, 2016 (72)	TMI	RCT	Hospital	30 TMI 30 TAU	VAS DAI-10	1.0	1.0	TM>TAU
Beebe *et al.* 2017 (73)	Weekly TIPS	RCT	OPD	105 Total	Pill-count Drug assay	6.0	6.0	Pill count: TIPS = TAU Assays: TIPS>TAU (54.7%, 32.7%)
Kidd *et al.* 2018 (74)	CATC vs. Support	RCT	OPD	10 CATC 10	BARS	4.0	4.0	No difference

					Support				
Xu *et al.* 2019 (75)	LEAN	RCT	OPD	271 Total	Pill-count	6.0	6.0	LEAN>TAU
Uslu *et al.* 2020 (76)	Weekly TIPS vs. TAU	RCT	OPD	22 TIPS 24 TAU	MARS	2.0	2.0	TIPS>TAU

8. Substance Abuse And Illness-Severity

Co-occurring substance use in schizophrenia patients has been frequently associated to poor treatment adherence and clinical outcomes (Clifford *et al.*, 2020; Czobor *et al.*, 2015; Sendt *et al.*, 2015; Bright, 2017). Direct testing of particular therapies aiming at enhancing treatment adherence in schizophrenia patients with drug addiction is uncommon despite the relevance of this link. 55 individuals with schizophrenia and drug addiction were studied using a CBT-based, skill-training approach. When looking at the 34 participants who finished the therapy (62 percent), adherence was considerably higher at the three-month follow up, but there was no control group to compare it with (Shaner *et al.*, 2003). Study participants with schizophrenia who used illicit substances or alcohol were shown to have poor treatment adherence if their psychotic symptoms did not improve and their tolerance of antipsychotic side effects was lower than expected (Clifford *et al.*, 2020).

Adherence to antipsychotic therapy has a shaky relationship with demographics and the number of years spent unwell with psychosis (Sendt *et al.*, 2015). Treatment adherence was improved by behavioural treatments for psychotic illness patients in remote regions that facilitated access to more aggressive psychiatric care (Xu *et al.*, 2019). Symptom intensity has been consistently linked to lower treatment adherence, but neurocognitive deficits have been inconsistently linked to lower treatment adherence (16). Antipsychotic medication usage was related with higher treatment adherence when patients had favourable views about the medication and a good perception of its benefits (Sendt *et al.*, 2015).

To improve treatment compliance and patient satisfaction with their care, it is possible to use Shared Decision-Making procedures for anti-psychotic medication (Bright, 2017). Patients are involved in their own care by being given clear information and being listened to in order to get to a mutually agreed-upon course of action (Hiemke *et al.*, 2017). Evidence of greater patient satisfaction and increased treatment adherence have been found via the use of this technique, although more extensive follow-up and more precise outcome measurements are required to test these first impressions (Hiemke *et al.*, 2017)

9. Therapeutic Support And Healthcare Settings

Few studies have looked at how patients' living, or treatment settings impact their adherence to therapy. Treatment compliance in individuals with schizophrenia may be predicted by a strong therapeutic connection between the patient and the prescribing doctor (Clifford *et al.*, 2020; Phan, 2016; Tessier *et al.*, 2017). Nevertheless, therapies aiming at improving treatment adherence and focusing on

the therapeutic connection are still being explored. Patient-clinician therapy interactions might benefit from collaborative decision-making, but this has to be studied further to see if it has any effect on treatment adherence or clinical outcomes (Hiemke *et al.*, 2017). For those who are seriously mentally ill, family support or participation in treatment planning has been linked to increased treatment compliance (Sendt *et al.*, 2015; Uslu & Buldukoglu, 2020). Adherence rates in schizophrenia patients are currently unaffected by particular treatments for family members or carers (Uslu & Buldukoglu, 2020).

Patients with schizophrenia may benefit from improved treatment approaches and greater access to community mental health services. Due to the limited and difficult access to healthcare services in rural areas and among the low-income population in both, these standards have been judged particularly important (Xu *et al.*, 2019; Farooq *et al.*, 2011). Large samples of schizophrenia patients have shown increased treatment compliance and clinical results as a result of the use of ACT models (Valenstein *et al.*, 2011). With frequent home visits or even phone consultations with trained nurses promoting medication adherence, schizophrenia patients benefit from behavioural techniques (Table 3). Treatment adherence and clinical results have improved in remote locations with limited access to mental health care facilities that use electronic monitoring of patient treatment and progress in conjunction with caregiver training to oversee medication delivery (Xu *et al.*, 2019; Farooq *et al.*, 2011).

10. Artificial Intelligence/Intelligent Retrieval And Digital Tracking

AiCure, an AI platform, has been used to keep track of and encourage treatment compliance in people with schizophrenia who use mobile phones (Bain *et al.*, 2017). Patients with schizophrenia who were on an experimental, supplementary, orally delivered medicine were given the technique as part of an exploratory study (Bain *et al.*, 2017). AiCure uses face recognition technology to verify the administration of medication and creates encrypted data for each dosage event to be monitored immediately or later and perhaps intervene for six months, with the treatment adherence validated by assays of plasma drug concentrations. In one experiment, schizophrenia patients with poor treatment adherence were either AiCure or mDOT. AiCure had an average cumulative adherence rate of 90% and mDOT had an average cumulative adherence rate of 72% (a non-significant difference) (Bain *et al.*, 2017).

The Food and Drug Administration has authorised a new formulation of SGA aripiprazole that includes a microsensor (Fowler *et al.*, 2019). With this device, physicians may electronically monitor medicine consumption and other parameters, such as activity levels and patient self-ratings of mood, thanks to a skin patch sensor (Fowler *et al.*, 2019). In three uncontrolled, open-label, two-month studies including seriously mentally ill participants, the technique has undergone preliminary testing for compliance with aripiprazole (Fowler *et al.*, 2019; Kopelowicz *et al.*, 2017; Peters-Strickland *et al.*, 2016). One study found that 74 percent of participants were able to appropriately utilise the therapy monitoring and were happy with it (Peters-Strickland *et al.*, 2016). For this revolutionary technology's therapeutic usefulness to be fully evaluated in terms of

treatment adherence and long-term results, more testing with appropriate controls and long-term outcomes is required (Kane *et al.*, 2020).

11. Conclusion

Failure of antipsychotic treatment in schizophrenia patients may lead to suicide, an increase in the need for professional services, and an increase in the cost to society. Patient features and professional services can contribute to poor adherence to medication treatment. If a patient ignores treatment guidelines for an extended period of time, both his or her health and financial well-being may suffer. Patients' adherence to medication has been studied in clinical studies using a wide range of drugs and techniques. In addition to LAIs, which have been demonstrated to improve treatment adherence and clinical outcomes, there are a slew of other possible treatments. It is well known that LAI medications may improve adherence, but they are not widely used because of their rigid dosing schedules and lack of attraction to patients. Products manufactured by LAI, Los Angeles International Pharmaceuticals. A long-term follow-up study of patients who have previously failed oral medication is thus required to compare oral to LAI antipsychotics and to evaluate the two types of treatments. Even while psychological and behavioral treatments have been shown to be beneficial via educational interventions, encouragement, and tighter professional supervision, their testing has been based on results of often questionable reliability and limited exposure. Therapeutic compliance is increasingly being improved by the use of technology. Mobile or other monitoring systems employing cell phones may also be used to keep tabs on patients' medication use and clinical progress. Traditional treatment strategies such as medication management, therapy, and technology-based procedures have no advantage over any of these other approaches in terms of either clinical or economic outcomes.

References

Abdel Aziz K, Elamin MH, El-Saadouni NM, El-Gabry DA, Barakat M, Alhayyas F, Moselhy HF. Schizophrenia: impact of psychopathology, faith-healers, and psychoeducation on adherence to medications. Int J Soc Psychiatry. 2016;62(8):719-25. doi: 10.1177/0020764016676215, PMID 27815512.

Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, Starr HL. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-61. doi: 10.4088/JCP.14m09584, PMID 25938474.

Anderson KH, Ford S, Robson D, *et al.* An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia. Int J Ment Health Nurs. 2010;19(5):340-9. Arch Psychiatr Nurs 2017;31: 99–110. doi: 10.1111/j.1447-0349.2010. 00681. x, PMID 20887608.

Bain EE, Shafner L, Walling DP, Othman AA, Chuang-Stein C, Hinkle J, Hanina A. Use of a novel artificial intelligence platform on mobile devices to assess dosing compliance in a Phase 2 clinical trial in subjects with schizophrenia. JMIR MHealth UHealth. 2017;5(2): e18. doi: 10.2196/mhealth.7030, PMID 28223265.

Baldessarini RJ. Chemotherapy in psychiatry. 3rd ed ed. New York: Springer Press; 2013.

Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. The Effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia. Schizophr Bull. 2013;39(6):1242-51. doi: 10.1093/schbul/sbt138, PMID 24072808.

Barkhof E, Meijer CJ, de Sonneville LMH, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia: review of the past decade. Eur Psychiatry. 2012;27(1):9-18. doi: 10.1016/j.eurpsy.2011.02.005, PMID 21561742.

Batara, R., Ardani, I. G. A. I., Wardani, I. A. K., Windiani, I. G. A. T., Adnyana, I. G. A. N. S., & Setiawati, Y. (2022). Psychogenic dysphagia in children, and the success of family-based treatment: Case report. International Journal of Health & Medical Sciences, 5(1), 163-168. https://doi.org/10.21744/ijhms.v5n1.1894

Beebe L, Smith KD, Phillips C. A Comparison of telephone and texting interventions for persons with schizophrenia spectrum disorders. Issues Ment Health Nurs. 2014;35(5):323-9. doi: 10.3109/01612840.2013.863412, PMID 24766166.

Beebe LH, Smith K, Phillips C. Effect of a telephone intervention upon self-reported medication adherence and self-efficacy in out-patients with schizophrenia spectrum disorders. Issues Ment Health Nurs. 2016;37(10):708-14. doi: 10.1080/01612840.2016.1214855, PMID 27532874.

Beebe LH, Smith K, Phillips C. Effect of a telephone intervention on measures of psychiatric and nonpsychiatric medication adherence in outpatients with schizophrenia spectrum disorders. J Psychosoc Nurs Ment Health Serv. 2017;55(1):29-36. doi: 10.3928/02793695-20170119-04, PMID 28135389.

Ben-Zeev D, Brenner CJ, Begale M, Duffecy J, Mohr DC, Mueser KT. Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. Schizophr Bull. 2014;40(6):1244-53. doi: 10.1093/schbul/sbu033, PMID 24609454.

Bickmore TW, Puskar K, Schlenk EA, Pfeifer LM, Sereika SM. Maintaining reality: relational agents for antipsychotic medication adherence. Interact Comput. 2010;22(4):276-88. doi: 10.1016/j.intcom.2010.02.001.

Brain C, Sameby B, Allerby K, Lindström E, Eberhard J, Burns T, Waern M. Twelve months of electronic monitoring (MEMS®) in the Swedish Coast-study: comparison of methods for the measurement of adherence in schizophrenia. Eur Neuropsychopharmacol. 2014;24(2):215-22. doi: 10.1016/j.euroneuro.2013.11.013, PMID 24359935.

Bright CE. Measuring medication adherence in patients with schizophrenia: an integrative review. Arch Psychiatr Nurs. 2017;31(1):99-110. doi: 10.1016/j.apnu.2016.09.003, PMID 28104068.

Çetin N, Aylaz R. The effect of mindfulness-based psychoeducation on insight and medication adherence of schizophrenia patients. Arch Psychiatr Nurs. 2018;32(5):737-44. doi: 10.1016/j.apnu.2018.04.011, PMID 30201202.

Chien WT, Cheung EFC, Mui JHC, Gray R, Ip G. Adherence therapy for schizophrenia: randomized controlled trial. Hong Kong Med J. 2019;25(1); Suppl 2:4-9. PMID 30674700.

Chien WT, Mui J, Gray R, Cheung E. Adherence therapy vs. routine psychiatric care for people with schizophrenia spectrum disorders: randomized controlled trial. BMC Psychiatry. 2016;16(1):42. doi: 10.1186/s12888-016-0744-6.

Chien WT, Mui JH, Cheung EF, Gray R. Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: randomized controlled trial. Trials. 2015;16(1):270. doi: 10.1186/s13063-015-0785-z, PMID 26072311.

Clifford L, Crabb S, Turnbull D, Hahn L, Galletly C. A Qualitative study of medication adherence amongst people with schizophrenia. Arch Psychiatr Nurs. 2020;34(4):194-9. doi: 10.1016/j.apnu.2020.06.002, PMID 32828348.

Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment adherence in schizophrenia: patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol. 2015;25(8):1158-66. doi: 10.1016/j.euroneuro.2015.04.003, PMID 26004980.

Dahan S, Behrbalk P, Stolovy T, Greenberger C. Improving adherence in hospitalized patients diagnosed with schizophrenia: an integrative one-on-one intervention. Arch Psychiatr Nurs. 2016;30(6):660-5. doi: 10.1016/j.apnu.2016.03.002, PMID 27888956.

El Khoury AC, Pilon D, Morrison L, Shak N, Llaneza A, Kim E, Lefebvre P. Projecting the long-term economic impact of once-monthly paliperidone palmitate vs. oral atypical antipsychotics in Medicaid patients with schizophrenia. J Manag Care Spec Pharm. 2020;26(2):176-85. doi: 10.18553/jmcp.2020.26.2.176, PMID 32011960.

Ertem MY, Duman ZÇ. Effect of motivational interviews on treatment adherence and insight levels of patients with schizophrenia: randomized controlled study. Perspect Psychiatr Care. 2019;55(1):75-86. doi: 10.1111/ppc.12301, PMID 29888541.

Farooq S, Nazar Z, Irfan M, Akhter J, Gul E, Irfan U, Naeem F. Schizophrenia medication adherence in a resource-poor setting: randomized controlled trial of supervised treatment in out-patients for schizophrenia (STOPS). Br J Psychiatry. 2011;199(6):467-72. doi: 10.1192/bjp.bp.110.085340, PMID 22130748.

Fiorillo A, Barlati S, Bellomo A, Corrivetti G, Nicolò G, Sampogna G, Stanga V, Veltro F, Maina G, Vita A. The Role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review. Ann Gen Psychiatry. 2020 May;19(1):43. doi: 10.1186/s12991-020-00293-4, PMID 32774442.

Fleischhacker WW. Adherence/compliance: a multifaceted challenge. World Psychiatry. 2013;12(3):232-3. doi: 10.1002/wps.20063, PMID 24096784.

Forsman J, Taipale H, Masterman T, Tiihonen J, Tanskanen A. Adherence to psychotropic medication in completed suicide in Sweden 2006-2013: a forensic-toxicological matched case-control study. Eur J Clin Pharmacol. 2019;75(10):1421-30. doi: 10.1007/s00228-019-02707-z, PMID 31218371.

Fowler JC, Cope N, Knights J, Phiri P, Makin A, Peters-Strickland T, Rathod S. Hummingbird Study: protocol for a multicenter exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder, or first-episode psychosis. BMJ Open. 2019;9(6): e025952. doi: 10.1136/bmjopen-2018-025952, PMID 31253613.

Granholm E, Ben-Zeev D, Link PC, Bradshaw KR, Holden JL. Mobile Assessment and Treatment for Schizophrenia (MATS): pilot trial of an interactive text-messaging intervention for medication adherence, socialization, and auditory hallucinations. Schizophr Bull. 2012;38(3):414-25. doi: 10.1093/schbul/sbr155, PMID 22080492.

Gray R, Bressington D, Ivanecka A, Hardy S, Jones M, Schulz M, von Bormann S, White J, Anderson KH, Chien WT. Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):90. doi: 10.1186/s12888-016-0801-1, PMID 27048373.

Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and dec- continuation of long-acting injectable vs. oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127-34. doi: 10.1080/13696998.2017.1379412, PMID 28895758.

Gutiérrez-Casares JR, Cañas F, Rodríguez-Morales A, Hidalgo-Borrajo R, Alonso-Escolano D. Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study. CNS Spectr. 2010;15(5):327-37. doi: 10.1017/s1092852900027553, PMID 20448523.

Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-2):9-62. doi: 10.1055/s-0043-116492, PMID 28910830.

Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200-18. doi: 10.1177/2045125312474019, PMID 24167693.

Kane JM, Correll CU. Comments on optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2020; 81:20lr13262a.

Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors, and management strategies. World Psychiatry. 2013;12(3):216-26. doi: 10.1002/wps.20060, PMID 24096780.

Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, Robinson DG. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217-24. doi: 10.1001/jamapsychiatry.2020.2076, PMID 32667636.

Kidd SA, Feldcamp L, Adler A, Kaleis L, Wang W, Vichnevetski K, McKenzie K, Voineskos A. Feasibility and outcomes of a multi-function mobile health approach for the schizophrenia spectrum: app4Independence (A4i). PLOS ONE. 2019;14(7): e0219491. doi: 10.1371/journal.pone.0219491, PMID 31306439.

Kidd SA, Kerman N, Ernest D, Maples N, Arthur C, de Souza S, Kath J, Herman Y, Virdee G, Collins A, Velligan D. A Pilot study of a family cognitive adaptation training guide for individuals with schizophrenia. Psychiatr Rehabil J. 2018;41(2):109-17. doi: 10.1037/prj0000204, PMID 27547853.

Kishimoto T, Hagi K, Nitta M, Leucht S, Olfson M, Kane JM, Correll CU. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: meta-analysis of prospective and retrospective cohort studies.

Schizophr Bull. 2018;44(3):603-19. doi: 10.1093/schbul/sbx090, PMID 29868849.

Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957-65. doi: 10.4088/JCP.13r08440, PMID 24229745.

Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. Long-acting injectable vs. oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192-213. doi: 10.1093/schbul/sbs150, PMID 23256986.

Kopelowicz A, Baker RA, Zhao C, Brewer C, Lawson E, Peters-Strickland T. A multicenter, open-label, pilot study evaluating the functionality of an integrated call center for a digital medicine system to optimize monitoring of adherence to oral aripiprazole in adult patients with serious mental illness. Neuropsychiatr Dis Treat. 2017; 13:2641-51. doi: 10.2147/NDT.S143091, PMID 29089771.

Kreyenbuhl J, Record EJ, Himelhoch S, Charlotte M, Palmer-Bacon J, Dixon LB, Medoff DR, Li L. Development and feasibility testing of a smartphone intervention to improve adherence to antipsychotic medications. Clin Schizophr Relat Psychoses. Winter;12(4):152-67. doi: 10.3371/CSRP.KRRE.070816, PMID 27454213.

Kreyenbuhl J, Record EJ, Palmer-Bacon J. A Review of behavioral tailoring strategies for improving medication adherence in serious mental illness. Dialog Clin Neurosci. Dialogues Clin Neurosci. 2016;18(2):191-201. doi: 10.31887/DCNS.2016.18.2/jkreyenbuhl, PMID 27489459.

Krzystanek M, Krysta K, Skałacka K. Treatment compliance in the long-term paranoid schizophrenia telemedicine study. J Technol Behav Sci. 2017;2(2):84-7. doi: 10.1007/s41347-017-0016-4, PMID 29082310.

Lee Y, Lee MS, Jeong HG, Youn HC, Kim SH. Medication adherence using electronic monitoring in severe psychiatric illness: 4 and 24 weeks after discharge. Clin Psychopharmacol Neurosci. 2019;17(2):288-96. doi: 10.9758/cpn.2019.17.2.288, PMID 30905129.

Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral vs. long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754-68. doi: 10.18553/jmcp.2015.21.9.754, PMID 26308223.

Mohr P, Knytl P, Voráčková V, Bravermanová A, Melicher T. Long-acting injectable antipsychotics for prevention and management of violent behavior in psychotic patients. Int J Clin Pract. 2017;71(9):e12997. doi: 10.1111/ijcp.12997, PMID 28869705.

Montes JM, Maurino J, Diez T, Saiz-Ruiz J. Telephone-based nursing strategy to improve adherence to antipsychotic treatment in schizophrenia: a controlled trial. Int J Psychiatry Clin Pract. 2010;14(4):274-81. doi: 10.3109/13651501.2010.505343, PMID 24917439.

Montes JM, Medina E, Gomez-Beneyto M, Maurino J. A Short Message Service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia. Psychiatry Res. 2012;200(2-3):89-95. doi: 10.1016/j.psychres.2012.07.034, PMID 22901437.

Nielsen J, Jensen SO, Friis RB, Valentin JB, Correll CU. Comparative effectiveness of risperidone long-acting injectable vs. first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull. 2015;41(3):627-36. doi: 10.1093/schbul/sbu128, PMID 25180312.

Ostuzzi G, Mazzi MA, Terlizzi S, Bertolini F, Aguglia A, Bartoli F, Bortolaso P, Callegari C, Caroleo M, Carrà G, Corbo M, D'Agostino A, Gastaldon C, Lucii C, Magliocco F, Martinotti G, Nosé M, Ostinelli EG, Papola D, Piccinelli MP, Piccoli A, Purgato M, Tabacchi T, Turrini G, Ruggeri M, Barbui C, STAR Network Investigators. Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. PLOS ONE. 2018;13(8):e0201371. doi: 10.1371/journal.pone.0201371, PMID 30071042.

Peters-Strickland T, Pestreich L, Hatch A, Rohatagi S, Baker RA, Docherty JP, Markovtsova L, Raja P, Weiden PJ, Walling DP. Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. Neuropsychiatr Dis Treat. 2016; 12:2587-94. doi: 10.2147/NDT.S116029, PMID 27785036.

Phan SV. Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 2016;51(2):211-9. doi: 10.1177/0091217416636601.

Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K. Treatment patterns, health- care resource utilization, and spending in Medicaid beneficiaries initiating second-generation long-acting injectable agents vs. oral atypical antipsychotics. Clin Ther. 2017;39(10):1972-1985.e2. doi: 10.1016/j.clinthera.2017.08.008, PMID 28919292.

Priebe S, Bremner SA, Lauber C, Henderson C, Burns T. Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomized controlled trial. Health Technol Assess. 2016;20(70):1-122. doi: 10.3310/hta20700, PMID 27682868.

Priebe S, Yeeles K, Bremner S, Lauber C, Eldridge S, Ashby D, David AS, O'Connell N, Forrest A, Burns T. Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: a cluster randomized controlled trial. BMJ. 2013;347(October 07-3): f5847. doi: 10.1136/bmj.f5847, PMID 24100934.

Schulz M, Gray R, Spiekermann A, Abderhalden C, Behrens J, Driessen M. Adherence therapy following an acute episode of schizophrenia: a multi-center randomized controlled trial. Schizophr Res. 2013;146(1-3):59-63. doi: 10.1016/j.schres.2013.01.028, PMID 23452506.

Sendt KV, Tracy DK, Bhattacharyya S. A Systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225(1-2):14-30. doi: 10.1016/j.psychres.2014.11.002, PMID 25466227.

Shah A, Xie L, Kariburyo F, Zhang Q, Gore M. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable vs. oral antipsychotics. Adv Ther. 2018;35(11):1994-2014. doi: 10.1007/s12325-018-0786-x, PMID 30269292.

Shaner A, Eckman T, Roberts LJ, Fuller T. Feasibility of a skills training approach to reduce substance dependence among individuals with schizophrenia. Psychiatr Serv. 2003;54(9):1287-9. doi: 10.1176/appi.ps.54.9.1287, PMID 12954948.

Song X, El Khoury AC, Brouillette M, Smith D, Joshi K. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. J Med Econ. 2019;22(11):1105-12. doi: 10.1080/13696998.2019.1615927, PMID 31062998.

Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW, Loonen AJ, Mulder CL. Treatment adherence therapy in people with psychotic disorders: randomized controlled trial. Br J Psychiatry. 2010;197(6):448-55. doi: 10.1192/bjp.bp.110.077289, PMID 21119150.

Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, Nuechterlein KH. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: randomized clinical trial. JAMA Psychiatry. 2015;72(8):822-9. doi: 10.1001/jamapsychiatry.2015.0270, PMID 26107752.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938

Suzuki H, Hibino H, Inoue Y, Takaya A. Treatment continuation of 3 second-generation antipsychotic long-acting injections, and Oral paliperidone in patients with schizophrenia for 2 years. J Clin Psychopharmacol. 2018;38(6):649-50. doi: 10.1097/JCP.0000000000000976, PMID 30334868.

Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61-8. doi: 10.1002/wps.20699, PMID 31922669.

Tatu M, Demir S. Effect of group psychoeducation on treatment adherence, quality of life and wellbeing of patients diagnosed with schizophrenia. Issues Ment Health Nurs. 2020; 12:1-11.

Tessier A, Boyer L, Husky M, Baylé F, Llorca PM, Misdrahi D. Medication adherence in schizophrenia: role of insight, therapeutic alliance and perceived trauma associated with psychiatric care. Psychiatry Res. 2017; 257:315-21. doi: 10.1016/j.psychres.2017.07.063, PMID 28800510.

Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of antipsychotic polypharmacy vs. monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76(5):499-507. doi: 10.1001/jamapsychiatry.2018.4320, PMID 30785608.

Titus-Lay EN, Ansara ED, Isaacs AN, Ott CA. Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis. Ment Health Clin. 2018;8(2):56-62. doi: 10.9740/mhc.2018.03.056, PMID 29955546.

Tranulis C, Goff D, Henderson DC, Freudenreich O. Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients. Psychiatr Serv. 2011;62(8):888-92. doi: 10.1176/ps.62.8.pss6208_0888, PMID 21807827.

Uslu E, Buldukoglu K. Randomized controlled trial of the effects of nursing care based on a telephone intervention for medication adherence in schizophrenia. Perspect Psychiatr Care. 2020;56(1):63-71. doi: 10.1111/ppc.12376, PMID 30912160.

Valenstein M, Kavanagh J, Lee T, Reilly P, Dalack GW, Grabowski J, Smelson D, Ronis DL, Ganoczy D, Woltmann E, Metreger T, Wolschon P, Jensen A, Poddig B, Blow FC. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull. 2011;37(4):727-36. doi: 10.1093/schbul/sbp121, PMID 19933540.

Velligan D, Mintz J, Maples N, Xueying L, Gajewski S, Carr H, Sierra C. Randomized trial comparing in-person and electronic interventions for improving adherence to oral medications in schizophrenia. Schizophr Bull. 2013;39(5):999-1007. doi: 10.1093/schbul/sbs116, PMID 23086987.

Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, Lam YW, Ereshefsky L, Miller AL. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007;58(9):1187-92. doi: 10.1176/ps.2007.58.9.1187, PMID 17766564.

Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP, Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. The expert consensus guideline series. J Clin Psychiatry. 2009;70; Suppl 4:1-46; quiz 47. PMID 19686636.

Verdoux H, Pambrun E, Tournier M, Bezin J, Pariente A. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study. Acta Psychiatr Scand. 2017;135(5):429-38. doi: 10.1111/acps.12722, PMID 28332704.

Vincent PD, Demers MF, Doyon-Kemp V, Duchesneau J, Halme A, Masson V. One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada. Schizophr Res. 2017; 185:96-100. doi: 10.1016/j.schres.2017.01.013, PMID 28119036.

von Bormann S, Robson D, Gray R. Adherence therapy following acute exacerbation of schizophrenia: a randomized controlled trial in Thailand. Int J Soc Psychiatry. 2015;61(1):3-9. doi: 10.1177/0020764014529099, PMID 24691494.

Xu DR, Xiao S, He H, Caine ED, Gloyd S, Simoni J, Hughes JP, Nie J, Lin M, He W, Yuan Y, Gong W. Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): a randomized controlled trial. PLOS Med. 2019;16(4): e1002785. doi: 10.1371/journal.pmed.1002785, PMID 31013275.

Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and dec- continuation of aripiprazole-once-monthly 400 mg vs. oral antipsychotics in patients with schizophrenia or bipolar I disorder: a real-world study using US claims data. Adv Ther. 2018;35(10):1612-25. doi: 10.1007/s12325-018-0785-y, PMID 30206822.

Yanagida N, Uchino T, Uchimura N. The effects of psychoeducation on long-term inpatients with schizophrenia and schizoaffective disorder. Kurume Med J. 2017;63(3)(3.4):61-7. doi: 10.2739/kurumemedj.MS00011, PMID 28381728.

Yıldız E, Aylaz R. How counseling based on acceptance and commitment therapy supported with motivational interviewing affects the perceptions of treatment motivation in patients diagnosed with schizophrenia: a qualitative study. J Am Psychiatr Nurs Assoc. 2021;107839032094538. (on-line ahead of print, 29 Jul);27(5):390-404. doi: 10.1177/1078390320945380, PMID 32727253.

Yoshimatsu K, Elser A, Thomas M, Dilley J, Barnes D, Ballinger A, Wozniak S, Mangurian C. Recovery-oriented outcomes associated with long-acting injectable antipsychotics in an urban safety-net population. Community Ment Health J. 2019;55(6):979-82. doi: 10.1007/s10597-019-00412-w, PMID 31102164.

Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treat. 2012; 2012:407171. doi: 10.1155/2012/407171.